Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials

Stroke

Volumn 48, Issue 7, 2017, Pages 2007-2012

  Broderick, Joseph P ^a   Adeoye, Opeolu ^a   Elm, Jordan ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

clinical trial; modified Rankin Scale; multimedia; stroke

Indexed keywords

ALTEPLASE; NASARUPLASE BETA; PLACEBO;

BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); EFFECT SIZE; ENDOVASCULAR SURGERY; EURO QOL 5D; HUMAN; NEURO QUALITY OF LIFE SCALE; OUTCOME ASSESSMENT; PATIENT CARE; PERCUTANEOUS THROMBECTOMY; POST HOC ANALYSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANKIN SCALE; RATING SCALE; REVIEW; SAMPLE SIZE; STANDARDIZATION; STROKE PATIENT; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HUMANS; STROKE; TREATMENT OUTCOME;

EID: 85021081163     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.117.017866     Document Type: Review

References (53)

1. Quinn TJ, Dawson J, Walters M. Dr John Rankin; his life, legacy and the 50th anniversary of the Rankin Stroke Scale. Scott Med J. 2008;53:44-47. doi: 10.1258/RSMSMJ.53.1.44.
2. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044-1054.
3. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
4. Harrison JK, McArthur KS, Quinn TJ. Assessment scales in stroke: clinimetric and clinical considerations. Clin Interv Aging. 2013;8:201-211. doi: 10.2147/CIA.S32405.
5. Quinn TJ, Dawson J, Walters MR, Lees KR. Reliability of the modified Rankin Scale: a systematic review. Stroke. 2009;40:3393-3395. doi: 10.1161/STROKEAHA.109.557256.
6. Saver JL, Filip B, Hamilton S, Yanes A, Craig S, Cho M, et al; FAST-MAG Investigators and Coordinators. Improving the reliability of stroke disability grading in clinical trials and clinical practice: the Rankin Focused Assessment (RFA). Stroke. 2010;41:992-995. doi: 10.1161/STROKEAHA.109.571364.
7. Wilson JT, Hareendran A, Hendry A, Potter J, Bone I, Muir KW. Reliability of the modified Rankin Scale across multiple raters: benefits of a structured interview. Stroke. 2005;36:777-781. doi: 10.1161/01.STR.0000157596.13234.95.
8. Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW, et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke. 2002;33:2243-2246.
9. Bruno A, Close B, Switzer JA, Hess DC, Gross H, Nichols FT 3rd, et al. Simplified modified Rankin Scale questionnaire correlates with stroke severity. Clin Rehabil. 2013;27:724-727. doi: 10.1177/0269215512470674.
10. Bruno A, Akinwuntan AE, Lin C, Close B, Davis K, Baute V, et al. Simplified modified rankin scale questionnaire: reproducibility over the telephone and validation with quality of life. Stroke. 2011;42:2276-2279. doi: 10.1161/STROKEAHA.111.613273.
11. Hanley DF, Lane K, McBee N, Ziai W, Tuhrim S, Lees KR, et al; CLEAR III Investigators. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet. 2017;389:603-611. doi: 10.1016/S0140-6736(16)32410-2.
12. NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333: 1581-1587.
13. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
14. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al; Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368:893-903. doi: 10.1056/NEJMoa1214300.
15. Mendelow AD, Gregson BA, Rowan EN, Murray GD, Gholkar A, Mitchell PM; STICH II Investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet. 2013;382:397-408. doi: 10.1016/S0140-6736(13)60986-1.
16. Bath PM, Lees KR, Schellinger PD, Altman H, Bland M, Hogg C, et al; European Stroke Organisation Outcomes Working Group. Statistical analysis of the primary outcome in acute stroke trials. Stroke. 2012;43:1171-1178. doi: 10.1161/STROKEAHA.111.641456.
17. Optimising Analysis of Stroke Trials (OAST) Collaboration, Bath PM, Gray LJ, Collier T, Pocock S, Carpenter J. Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Stroke. 2007; 38: 1911-1915.
18. Howard G, Waller JL, Voeks JH, Howard VJ, Jauch EC, Lees KR, et al. A simple, assumption-free, and clinically interpretable approach for analysis of modified Rankin outcomes. Stroke. 2012;43:664-669. doi: 10.1161/STROKEAHA.111.632935.
19. Saver JL. Optimal end points for acute stroke therapy trials: best ways to measure treatment effects of drugs and devices. Stroke. 2011;42:2356-2362. doi: 10.1161/STROKEAHA.111.619122.
20. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al; SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562-571. doi: 10.1056/NEJMoa070240.
21. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al; Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600. doi: 10.1056/NEJMoa052980.
22. Chaisinanunkul N, Adeoye O, Lewis RJ, Grotta JC, Broderick J, Jovin TG, et al; DAWN Trial and MOST Trial Steering Committees; Additional contributors from DAWN Trial Steering Committee. Adopting a patientcentered approach to primary outcome analysis of Acute Stroke Trials using a utility-weighted modified Rankin Scale. Stroke. 2015;46:2238-2243. doi: 10.1161/STROKEAHA.114.008547.
23. Feeny D. A utility approach to the assessment of health-related quality of life. Med Care. 2000; 38: II151-4.
24. Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, et al; STAIR VII Consortium. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke. 2011;42:2645-2650. doi: 10.1161/STROKEAHA.111.618850.
25. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-343.
26. Ali M, MacIsaac R, Terence J Quinn TJ, Bath PM, Veenstra DL, Xu Y, et al; on behalf of the VISTA Collaborators. Dependency and health utilities in stroke: Data to inform cost-effectiveness analyses European Stroke. 2017;2:70-76
27. Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell PM, Luengo-Fernandez R. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making. 2010;30:341-354. doi: 10.1177/0272989X09349961.
28. Hong KS, Saver JL. Quantifying the value of stroke disability outcomes: WHO global burden of disease project disability weights for each level of the modified Rankin Scale. Stroke. 2009;40:3828-3833. doi: 10.1161/STROKEAHA.109.561365.
29. Prieto L, Sacristán JA. Problems and solutions in calculating qualityadjusted life years (QALYs). Health Qual Life Outcomes. 2003;1:80. doi: 10.1186/1477-7525-1-80.
30. Klarman HE. The road to cost-effectiveness analysis. Milbank Mem Fund Q Health Soc. 1982;60:585-603.
31. Greenberg D, Pliskin JS. Preference-based outcome measures in costutility analyses. A 20-year overview. Int J Technol Assess Health Care. 2002;18:461-466.
32. Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res. 1972;7:118-133.
33. Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev Pharmacoecon Outcomes Res. 2002;2:99-108. doi: 10.1586/14737167.2.2.99.
34. Kwiatkowski T, Libman R, Frankel M, Tilley B, Morganstern L, Lu M, et al. NINDS rt-PA Stroke Study Group. The NINDS rt-PA Stroke Study: Sustained Benefit at One Year. Stroke. 1998; 29: 288.
35. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology. 1994;44:626-634.
36. Lees KR, Selim MH, Molina CA, Broderick JP. Early versus late assessment of stroke outcome. Stroke. 2016;47:1416-1419. doi: 10.1161/STROKEAHA.115.011153.
37. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372:2285-2295. doi: 10.1056/NEJMoa1415061.
38. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019-1030. doi: 10.1056/NEJMoa1414905.
39. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11-20. doi: 10.1056/NEJMoa1411587.
40. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372:2296-2306. doi: 10.1056/NEJMoa1503780.
41. Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, Moulin T, et al; THRACE Investigators. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol. 2016;15:1138-1147. doi: 10.1016/S1474-4422(16)30177-6.
42. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355-2365. doi: 10.1056/NEJMoa1214609.
43. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al; IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379:2352-2363. doi: 10.1016/S0140-6736(12)60768-5.
44. Demchuk AM, Goyal M, Yeatts SD, Carrozzella J, Foster LD, Qazi E, et al; IMS III Investigators. Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. Radiology. 2014;273:202-210. doi: 10.1148/radiol.14132649.
45. Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, et al; TREVO 2 Trialists. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet. 2012;380:1231-1240. doi: 10.1016/S0140-6736(12)61299-9.
46. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329. doi: 10.1056/NEJMoa0804656.
47. Anderson CS, Robinson T, Lindley RI, Arima H, Lavados PM, Lee TH, et al; ENCHANTED Investigators and Coordinators. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med. 2016;374:2313-2323. doi: 10.1056/NEJMoa1515510.
48. Ginsberg MD, Palesch YY, Hill MD, Martin RH, Moy CS, Barsan WG, et al; ALIAS and Neurological Emergencies Treatment Trials (NETT) Investigators. High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebocontrolled trial. Lancet Neurol. 2013;12:1049-1058. doi: 10.1016/S1474-4422(13)70223-0.
49. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al; ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375:1033-1043. doi: 10.1056/NEJMoa1603460.
50. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al; FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127-2137. doi: 10.1056/NEJMoa0707534.
51. Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, et al; INTERACT Investigators. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008;7:391-399. doi: 10.1016/S1474-4422(08)70069-3.
52. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, et al; STICH Investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005;365:387-397. doi: 10.1016/S0140-6736(05)17826-X.
53. Gershon RC, Lai JS, Bode R, Choi S, Moy C, Bleck T, et al. Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res. 2012;21:475-486. doi: 10.1007/s11136-011-9958-8.